Skip to main content
Signal8

INSULET CORP (PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Insulet Corp. logo

Insulet Corp.

NASDAQ:PODDHealthcare
-1.85%$149.68
AH$149.68+0.00%vs close
Mkt Cap$10.38B
Float69.1M
O/S69.35M
Vol
$ Vol
RVOL
Inst Own-
SI8.2%
Earnings
Dilution
FormDescription
13G/A
Beneficial Ownership Report (Amended)
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
8-K
8-K
8-K
4
PRIMARY DOCUMENT
13G/A
Beneficial Ownership Report (Amended)
10-Q
8-K
2.02,9.01
4
PRIMARY DOCUMENT
4/A
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
3
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
8-K
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
144
Notice of Proposed Sale of Securities
SD
SEC Filing
8-K
7.01,9.01
5
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT

1-25 of 1,749

…

Recent SEC filings with analysis